nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—Prednisone—systemic scleroderma	0.362	1	CrCtD
Danazol—CCL2—systemic scleroderma	0.323	1	CbGaD
Danazol—Testolactone—Mometasone—systemic scleroderma	0.0356	0.181	CrCrCtD
Danazol—Fluoxymesterone—Mometasone—systemic scleroderma	0.0327	0.166	CrCrCtD
Danazol—Prednisone—Mometasone—systemic scleroderma	0.0318	0.162	CrCrCtD
Danazol—Hydrocortisone—Mometasone—systemic scleroderma	0.026	0.132	CrCrCtD
Danazol—Cortisone acetate—Prednisone—systemic scleroderma	0.02	0.102	CrCrCtD
Danazol—Testolactone—Prednisone—systemic scleroderma	0.0194	0.0987	CrCrCtD
Danazol—Methyltestosterone—Prednisone—systemic scleroderma	0.0169	0.0861	CrCrCtD
Danazol—Hydrocortisone—Prednisone—systemic scleroderma	0.0142	0.072	CrCrCtD
Danazol—CCL2—alveolus of lung—systemic scleroderma	0.0101	0.299	CbGeAlD
Danazol—CCL2—skeletal joint—systemic scleroderma	0.00535	0.159	CbGeAlD
Danazol—CCL2—artery—systemic scleroderma	0.00224	0.0664	CbGeAlD
Danazol—CCL2—endothelium—systemic scleroderma	0.00189	0.0561	CbGeAlD
Danazol—CCL2—blood vessel—systemic scleroderma	0.00175	0.0517	CbGeAlD
Danazol—ESR1—FOXM1 transcription factor network—CENPB—systemic scleroderma	0.0012	0.066	CbGpPWpGaD
Danazol—PGR—artery—systemic scleroderma	0.00118	0.0349	CbGeAlD
Danazol—PGR—blood vessel—systemic scleroderma	0.000917	0.0272	CbGeAlD
Danazol—CCL2—connective tissue—systemic scleroderma	0.000895	0.0265	CbGeAlD
Danazol—CCL2—Spinal Cord Injury—AIF1—systemic scleroderma	0.000892	0.049	CbGpPWpGaD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—COL1A2—systemic scleroderma	0.000865	0.0475	CbGpPWpGaD
Danazol—CCL2—smooth muscle tissue—systemic scleroderma	0.000819	0.0243	CbGeAlD
Danazol—CCL2—skin of body—systemic scleroderma	0.000808	0.024	CbGeAlD
Danazol—CCL2—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.000785	0.0431	CbGpPWpGaD
Danazol—ESR1—blood vessel—systemic scleroderma	0.000717	0.0213	CbGeAlD
Danazol—CCL2—IL23-mediated signaling events—STAT4—systemic scleroderma	0.000691	0.0379	CbGpPWpGaD
Danazol—CCL2—digestive system—systemic scleroderma	0.000646	0.0192	CbGeAlD
Danazol—CCL2—tendon—systemic scleroderma	0.000615	0.0182	CbGeAlD
Danazol—CCL2—Folate Metabolism—CSF1—systemic scleroderma	0.000596	0.0327	CbGpPWpGaD
Danazol—CCL2—lung—systemic scleroderma	0.00054	0.016	CbGeAlD
Danazol—SHBG—connective tissue—systemic scleroderma	0.000522	0.0155	CbGeAlD
Danazol—CCL2—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000519	0.0285	CbGpPWpGaD
Danazol—PGR—connective tissue—systemic scleroderma	0.00047	0.0139	CbGeAlD
Danazol—CCL2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000436	0.0239	CbGpPWpGaD
Danazol—PGR—smooth muscle tissue—systemic scleroderma	0.00043	0.0128	CbGeAlD
Danazol—CYP19A1—connective tissue—systemic scleroderma	0.000423	0.0125	CbGeAlD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP1—systemic scleroderma	0.000393	0.0216	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—SELP—systemic scleroderma	0.000388	0.0213	CbGpPWpGaD
Danazol—AR—connective tissue—systemic scleroderma	0.000375	0.0111	CbGeAlD
Danazol—ESR1—connective tissue—systemic scleroderma	0.000368	0.0109	CbGeAlD
Danazol—CCL2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000363	0.0199	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000355	0.0195	CbGpPWpGaD
Danazol—CCL2—IL1 and megakaryotyces in obesity—IL1B—systemic scleroderma	0.000343	0.0188	CbGpPWpGaD
Danazol—AR—smooth muscle tissue—systemic scleroderma	0.000343	0.0102	CbGeAlD
Danazol—CCL2—IL-1 signaling pathway—IL1A—systemic scleroderma	0.000339	0.0186	CbGpPWpGaD
Danazol—AR—skin of body—systemic scleroderma	0.000338	0.01	CbGeAlD
Danazol—ESR1—smooth muscle tissue—systemic scleroderma	0.000336	0.00998	CbGeAlD
Danazol—CCL2—IL1 and megakaryotyces in obesity—MMP9—systemic scleroderma	0.000324	0.0178	CbGpPWpGaD
Danazol—ESR1—FOXM1 transcription factor network—CENPA—systemic scleroderma	0.000317	0.0174	CbGpPWpGaD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—systemic scleroderma	0.000304	0.0167	CbGpPWpGaD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—systemic scleroderma	0.000285	0.0157	CbGpPWpGaD
Danazol—PGR—lung—systemic scleroderma	0.000284	0.00841	CbGeAlD
Danazol—CCL2—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000281	0.0154	CbGpPWpGaD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000278	0.0153	CbGpPWpGaD
Danazol—AR—digestive system—systemic scleroderma	0.000271	0.00802	CbGeAlD
Danazol—ESR1—digestive system—systemic scleroderma	0.000266	0.00788	CbGeAlD
Danazol—AR—tendon—systemic scleroderma	0.000258	0.00764	CbGeAlD
Danazol—CCL2—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000251	0.0138	CbGpPWpGaD
Danazol—CCL2—IL23-mediated signaling events—IL1B—systemic scleroderma	0.000243	0.0133	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000236	0.013	CbGpPWpGaD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—systemic scleroderma	0.000229	0.0126	CbGpPWpGaD
Danazol—AR—lung—systemic scleroderma	0.000226	0.0067	CbGeAlD
Danazol—ESR1—lung—systemic scleroderma	0.000222	0.00658	CbGeAlD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000214	0.0118	CbGpPWpGaD
Danazol—PGR—Cellular roles of Anthrax toxin—IL1B—systemic scleroderma	0.000212	0.0116	CbGpPWpGaD
Danazol—CCL2—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000207	0.0114	CbGpPWpGaD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000203	0.0111	CbGpPWpGaD
Danazol—AR—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.0002	0.011	CbGpPWpGaD
Danazol—CCL2—Methylprednisolone—Mometasone—systemic scleroderma	0.000194	0.0889	CbGdCrCtD
Danazol—CCL2—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000188	0.0103	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000184	0.0101	CbGpPWpGaD
Danazol—CCL2—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000177	0.0097	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000176	0.00965	CbGpPWpGaD
Danazol—CCL2—Beclomethasone—Mometasone—systemic scleroderma	0.000174	0.0797	CbGdCrCtD
Danazol—AR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000169	0.00928	CbGpPWpGaD
Danazol—CCL2—Fluocinonide—Mometasone—systemic scleroderma	0.00016	0.0735	CbGdCrCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000157	0.00863	CbGpPWpGaD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000156	0.00858	CbGpPWpGaD
Danazol—CCL2—Amcinonide—Mometasone—systemic scleroderma	0.000154	0.0705	CbGdCrCtD
Danazol—CCL2—Folate Metabolism—IL1B—systemic scleroderma	0.000153	0.00839	CbGpPWpGaD
Danazol—CYP3A4—digestive system—systemic scleroderma	0.000148	0.00439	CbGeAlD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000145	0.00799	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—MMP9—systemic scleroderma	0.000137	0.00754	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00013	0.00715	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000126	0.00694	CbGpPWpGaD
Danazol—CCL2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000121	0.00666	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000121	0.00665	CbGpPWpGaD
Danazol—CCL2—Fluorometholone—Mometasone—systemic scleroderma	0.00012	0.0551	CbGdCrCtD
Danazol—GNRHR—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000117	0.00643	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—TGFB1—systemic scleroderma	0.000113	0.00622	CbGpPWpGaD
Danazol—Tension—Mycophenolic acid—systemic scleroderma	0.000106	0.00166	CcSEcCtD
Danazol—Erythema multiforme—Lisinopril—systemic scleroderma	0.000106	0.00165	CcSEcCtD
Danazol—CCL2—Methylprednisolone—Prednisone—systemic scleroderma	0.000106	0.0484	CbGdCrCtD
Danazol—Nervousness—Mycophenolic acid—systemic scleroderma	0.000105	0.00164	CcSEcCtD
Danazol—Pruritus—Pentoxifylline—systemic scleroderma	0.000105	0.00164	CcSEcCtD
Danazol—Sweating—Mycophenolate mofetil—systemic scleroderma	0.000105	0.00164	CcSEcCtD
Danazol—Back pain—Mycophenolic acid—systemic scleroderma	0.000105	0.00164	CcSEcCtD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000105	0.00575	CbGpPWpGaD
Danazol—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.000104	0.00163	CcSEcCtD
Danazol—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.000104	0.00163	CcSEcCtD
Danazol—Flushing—Lisinopril—systemic scleroderma	0.000104	0.00162	CcSEcCtD
Danazol—AR—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000103	0.00564	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000103	0.0016	CcSEcCtD
Danazol—Arthralgia—Azathioprine—systemic scleroderma	0.000103	0.0016	CcSEcCtD
Danazol—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000102	0.00159	CcSEcCtD
Danazol—Vertigo—Leflunomide—systemic scleroderma	0.000102	0.00159	CcSEcCtD
Danazol—Leukopenia—Leflunomide—systemic scleroderma	0.000102	0.00159	CcSEcCtD
Danazol—Tremor—Mycophenolic acid—systemic scleroderma	0.000102	0.00158	CcSEcCtD
Danazol—CCL2—Clobetasol propionate—Mometasone—systemic scleroderma	0.000102	0.0466	CbGdCrCtD
Danazol—Body temperature increased—Mometasone—systemic scleroderma	0.000101	0.00158	CcSEcCtD
Danazol—Paraesthesia—Captopril—systemic scleroderma	0.000101	0.00158	CcSEcCtD
Danazol—Chills—Lisinopril—systemic scleroderma	0.000101	0.00157	CcSEcCtD
Danazol—Palpitations—Leflunomide—systemic scleroderma	0.000101	0.00157	CcSEcCtD
Danazol—CCL2—Flunisolide—Mometasone—systemic scleroderma	0.0001	0.046	CbGdCrCtD
Danazol—CCL2—Triamcinolone—Mometasone—systemic scleroderma	9.92e-05	0.0455	CbGdCrCtD
Danazol—Alopecia—Lisinopril—systemic scleroderma	9.92e-05	0.00155	CcSEcCtD
Danazol—Dyspepsia—Captopril—systemic scleroderma	9.91e-05	0.00155	CcSEcCtD
Danazol—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	9.89e-05	0.00154	CcSEcCtD
Danazol—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	9.84e-05	0.00153	CcSEcCtD
Danazol—Dizziness—Pentoxifylline—systemic scleroderma	9.83e-05	0.00153	CcSEcCtD
Danazol—Hypertension—Leflunomide—systemic scleroderma	9.82e-05	0.00153	CcSEcCtD
Danazol—Vertigo—Mycophenolic acid—systemic scleroderma	9.75e-05	0.00152	CcSEcCtD
Danazol—Syncope—Mycophenolic acid—systemic scleroderma	9.73e-05	0.00152	CcSEcCtD
Danazol—Leukopenia—Mycophenolic acid—systemic scleroderma	9.71e-05	0.00151	CcSEcCtD
Danazol—Fatigue—Captopril—systemic scleroderma	9.71e-05	0.00151	CcSEcCtD
Danazol—Arthralgia—Leflunomide—systemic scleroderma	9.68e-05	0.00151	CcSEcCtD
Danazol—CCL2—Fluticasone Propionate—Mometasone—systemic scleroderma	9.68e-05	0.0444	CbGdCrCtD
Danazol—Anxiety—Leflunomide—systemic scleroderma	9.65e-05	0.0015	CcSEcCtD
Danazol—Constipation—Captopril—systemic scleroderma	9.63e-05	0.0015	CcSEcCtD
Danazol—Thrombocytopenia—Azathioprine—systemic scleroderma	9.62e-05	0.0015	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—IL1B—systemic scleroderma	9.6e-05	0.00527	CbGpPWpGaD
Danazol—Tension—Lisinopril—systemic scleroderma	9.59e-05	0.00149	CcSEcCtD
Danazol—Palpitations—Mycophenolic acid—systemic scleroderma	9.59e-05	0.00149	CcSEcCtD
Danazol—Loss of consciousness—Mycophenolic acid—systemic scleroderma	9.54e-05	0.00149	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—EDN1—systemic scleroderma	9.52e-05	0.00522	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	9.49e-05	0.00521	CbGpPWpGaD
Danazol—Nervousness—Lisinopril—systemic scleroderma	9.49e-05	0.00148	CcSEcCtD
Danazol—Affect lability—Prednisone—systemic scleroderma	9.49e-05	0.00148	CcSEcCtD
Danazol—Visual impairment—Mycophenolate mofetil—systemic scleroderma	9.48e-05	0.00148	CcSEcCtD
Danazol—Back pain—Lisinopril—systemic scleroderma	9.45e-05	0.00147	CcSEcCtD
Danazol—Vomiting—Pentoxifylline—systemic scleroderma	9.45e-05	0.00147	CcSEcCtD
Danazol—CCL2—Desoximetasone—Mometasone—systemic scleroderma	9.42e-05	0.0432	CbGdCrCtD
Danazol—Convulsion—Mycophenolic acid—systemic scleroderma	9.4e-05	0.00147	CcSEcCtD
Danazol—Muscle spasms—Lisinopril—systemic scleroderma	9.4e-05	0.00146	CcSEcCtD
Danazol—Rash—Pentoxifylline—systemic scleroderma	9.37e-05	0.00146	CcSEcCtD
Danazol—Hypertension—Mycophenolic acid—systemic scleroderma	9.37e-05	0.00146	CcSEcCtD
Danazol—Dermatitis—Pentoxifylline—systemic scleroderma	9.36e-05	0.00146	CcSEcCtD
Danazol—ESR1—FOXM1 transcription factor network—MMP2—systemic scleroderma	9.31e-05	0.00511	CbGpPWpGaD
Danazol—Headache—Pentoxifylline—systemic scleroderma	9.31e-05	0.00145	CcSEcCtD
Danazol—Arthralgia—Mycophenolic acid—systemic scleroderma	9.24e-05	0.00144	CcSEcCtD
Danazol—Vision blurred—Lisinopril—systemic scleroderma	9.21e-05	0.00144	CcSEcCtD
Danazol—Anxiety—Mycophenolic acid—systemic scleroderma	9.21e-05	0.00143	CcSEcCtD
Danazol—Asthenia—Mometasone—systemic scleroderma	9.2e-05	0.00143	CcSEcCtD
Danazol—Irritability—Prednisone—systemic scleroderma	9.2e-05	0.00143	CcSEcCtD
Danazol—Photosensitivity—Methotrexate—systemic scleroderma	9.17e-05	0.00143	CcSEcCtD
Danazol—Tremor—Lisinopril—systemic scleroderma	9.16e-05	0.00143	CcSEcCtD
Danazol—CCL2—Diflorasone—Mometasone—systemic scleroderma	9.15e-05	0.0419	CbGdCrCtD
Danazol—PGR—Generic Transcription Pathway—SMAD7—systemic scleroderma	9.13e-05	0.00501	CbGpPWpGaD
Danazol—Mood swings—Prednisone—systemic scleroderma	9.13e-05	0.00142	CcSEcCtD
Danazol—Thrombocytopenia—Leflunomide—systemic scleroderma	9.09e-05	0.00142	CcSEcCtD
Danazol—Pruritus—Mometasone—systemic scleroderma	9.07e-05	0.00141	CcSEcCtD
Danazol—Tachycardia—Leflunomide—systemic scleroderma	9.06e-05	0.00141	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—MMP9—systemic scleroderma	9.05e-05	0.00497	CbGpPWpGaD
Danazol—Hyperhidrosis—Leflunomide—systemic scleroderma	8.97e-05	0.0014	CcSEcCtD
Danazol—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	8.96e-05	0.0014	CcSEcCtD
Danazol—Body temperature increased—Captopril—systemic scleroderma	8.9e-05	0.00139	CcSEcCtD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	8.89e-05	0.00488	CbGpPWpGaD
Danazol—Oedema—Mycophenolic acid—systemic scleroderma	8.86e-05	0.00138	CcSEcCtD
Danazol—Nausea—Pentoxifylline—systemic scleroderma	8.83e-05	0.00138	CcSEcCtD
Danazol—Chills—Mycophenolate mofetil—systemic scleroderma	8.83e-05	0.00138	CcSEcCtD
Danazol—Vertigo—Lisinopril—systemic scleroderma	8.78e-05	0.00137	CcSEcCtD
Danazol—Syncope—Lisinopril—systemic scleroderma	8.76e-05	0.00137	CcSEcCtD
Danazol—Leukopenia—Lisinopril—systemic scleroderma	8.75e-05	0.00136	CcSEcCtD
Danazol—Shock—Mycophenolic acid—systemic scleroderma	8.71e-05	0.00136	CcSEcCtD
Danazol—Alopecia—Mycophenolate mofetil—systemic scleroderma	8.69e-05	0.00135	CcSEcCtD
Danazol—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	8.67e-05	0.00135	CcSEcCtD
Danazol—Tachycardia—Mycophenolic acid—systemic scleroderma	8.64e-05	0.00135	CcSEcCtD
Danazol—Palpitations—Lisinopril—systemic scleroderma	8.64e-05	0.00135	CcSEcCtD
Danazol—Loss of consciousness—Lisinopril—systemic scleroderma	8.59e-05	0.00134	CcSEcCtD
Danazol—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	8.56e-05	0.00133	CcSEcCtD
Danazol—Visual disturbance—Methotrexate—systemic scleroderma	8.5e-05	0.00132	CcSEcCtD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	8.48e-05	0.00466	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	8.46e-05	0.00132	CcSEcCtD
Danazol—Tension—Mycophenolate mofetil—systemic scleroderma	8.4e-05	0.00131	CcSEcCtD
Danazol—CCL2—Amcinonide—Prednisone—systemic scleroderma	8.38e-05	0.0384	CbGdCrCtD
Danazol—Paraesthesia—Leflunomide—systemic scleroderma	8.34e-05	0.0013	CcSEcCtD
Danazol—Arthralgia—Lisinopril—systemic scleroderma	8.32e-05	0.0013	CcSEcCtD
Danazol—Nervousness—Mycophenolate mofetil—systemic scleroderma	8.32e-05	0.0013	CcSEcCtD
Danazol—Anxiety—Lisinopril—systemic scleroderma	8.29e-05	0.00129	CcSEcCtD
Danazol—Back pain—Mycophenolate mofetil—systemic scleroderma	8.28e-05	0.00129	CcSEcCtD
Danazol—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	8.23e-05	0.00128	CcSEcCtD
Danazol—Dyspepsia—Leflunomide—systemic scleroderma	8.17e-05	0.00127	CcSEcCtD
Danazol—Pancreatitis—Prednisone—systemic scleroderma	8.17e-05	0.00127	CcSEcCtD
Danazol—Vomiting—Mometasone—systemic scleroderma	8.15e-05	0.00127	CcSEcCtD
Danazol—Rash—Mometasone—systemic scleroderma	8.09e-05	0.00126	CcSEcCtD
Danazol—Asthenia—Captopril—systemic scleroderma	8.08e-05	0.00126	CcSEcCtD
Danazol—Dermatitis—Mometasone—systemic scleroderma	8.08e-05	0.00126	CcSEcCtD
Danazol—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	8.07e-05	0.00126	CcSEcCtD
Danazol—Headache—Mometasone—systemic scleroderma	8.03e-05	0.00125	CcSEcCtD
Danazol—Tremor—Mycophenolate mofetil—systemic scleroderma	8.02e-05	0.00125	CcSEcCtD
Danazol—CCL2—Budesonide—Mometasone—systemic scleroderma	8.02e-05	0.0368	CbGdCrCtD
Danazol—Fatigue—Leflunomide—systemic scleroderma	8e-05	0.00125	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—MMP1—systemic scleroderma	8e-05	0.00439	CbGpPWpGaD
Danazol—Oedema—Lisinopril—systemic scleroderma	7.98e-05	0.00124	CcSEcCtD
Danazol—Pruritus—Captopril—systemic scleroderma	7.97e-05	0.00124	CcSEcCtD
Danazol—Paraesthesia—Mycophenolic acid—systemic scleroderma	7.95e-05	0.00124	CcSEcCtD
Danazol—Constipation—Leflunomide—systemic scleroderma	7.94e-05	0.00124	CcSEcCtD
Danazol—Shock—Lisinopril—systemic scleroderma	7.85e-05	0.00122	CcSEcCtD
Danazol—Thrombocytopenia—Lisinopril—systemic scleroderma	7.81e-05	0.00122	CcSEcCtD
Danazol—Dyspepsia—Mycophenolic acid—systemic scleroderma	7.8e-05	0.00121	CcSEcCtD
Danazol—Tachycardia—Lisinopril—systemic scleroderma	7.78e-05	0.00121	CcSEcCtD
Danazol—Body temperature increased—Azathioprine—systemic scleroderma	7.77e-05	0.00121	CcSEcCtD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	7.76e-05	0.00426	CbGpPWpGaD
Danazol—Hyperhidrosis—Lisinopril—systemic scleroderma	7.71e-05	0.0012	CcSEcCtD
Danazol—Vertigo—Mycophenolate mofetil—systemic scleroderma	7.69e-05	0.0012	CcSEcCtD
Danazol—Irritability—Methotrexate—systemic scleroderma	7.69e-05	0.0012	CcSEcCtD
Danazol—Syncope—Mycophenolate mofetil—systemic scleroderma	7.68e-05	0.0012	CcSEcCtD
Danazol—Leukopenia—Mycophenolate mofetil—systemic scleroderma	7.66e-05	0.00119	CcSEcCtD
Danazol—Fatigue—Mycophenolic acid—systemic scleroderma	7.63e-05	0.00119	CcSEcCtD
Danazol—Mood swings—Methotrexate—systemic scleroderma	7.63e-05	0.00119	CcSEcCtD
Danazol—Nausea—Mometasone—systemic scleroderma	7.62e-05	0.00119	CcSEcCtD
Danazol—Weight increased—Prednisone—systemic scleroderma	7.58e-05	0.00118	CcSEcCtD
Danazol—Constipation—Mycophenolic acid—systemic scleroderma	7.57e-05	0.00118	CcSEcCtD
Danazol—Palpitations—Mycophenolate mofetil—systemic scleroderma	7.57e-05	0.00118	CcSEcCtD
Danazol—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	7.53e-05	0.00117	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—TGFB1—systemic scleroderma	7.46e-05	0.00409	CbGpPWpGaD
Danazol—Dizziness—Captopril—systemic scleroderma	7.45e-05	0.00116	CcSEcCtD
Danazol—Convulsion—Mycophenolate mofetil—systemic scleroderma	7.42e-05	0.00116	CcSEcCtD
Danazol—Hypertension—Mycophenolate mofetil—systemic scleroderma	7.39e-05	0.00115	CcSEcCtD
Danazol—Urticaria—Leflunomide—systemic scleroderma	7.37e-05	0.00115	CcSEcCtD
Danazol—Body temperature increased—Leflunomide—systemic scleroderma	7.34e-05	0.00114	CcSEcCtD
Danazol—Acute coronary syndrome—Prednisone—systemic scleroderma	7.32e-05	0.00114	CcSEcCtD
Danazol—Arthralgia—Mycophenolate mofetil—systemic scleroderma	7.29e-05	0.00114	CcSEcCtD
Danazol—Myocardial infarction—Prednisone—systemic scleroderma	7.28e-05	0.00113	CcSEcCtD
Danazol—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	7.27e-05	0.00113	CcSEcCtD
Danazol—Anxiety—Mycophenolate mofetil—systemic scleroderma	7.27e-05	0.00113	CcSEcCtD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	7.22e-05	0.00396	CbGpPWpGaD
Danazol—Paraesthesia—Lisinopril—systemic scleroderma	7.16e-05	0.00112	CcSEcCtD
Danazol—Vomiting—Captopril—systemic scleroderma	7.16e-05	0.00112	CcSEcCtD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	7.14e-05	0.00392	CbGpPWpGaD
Danazol—Rash—Captopril—systemic scleroderma	7.1e-05	0.00111	CcSEcCtD
Danazol—ESR1—ATF-2 transcription factor network—MMP2—systemic scleroderma	7.1e-05	0.0039	CbGpPWpGaD
Danazol—Dermatitis—Captopril—systemic scleroderma	7.09e-05	0.00111	CcSEcCtD
Danazol—Headache—Captopril—systemic scleroderma	7.06e-05	0.0011	CcSEcCtD
Danazol—Dyspepsia—Lisinopril—systemic scleroderma	7.02e-05	0.00109	CcSEcCtD
Danazol—Body temperature increased—Mycophenolic acid—systemic scleroderma	7e-05	0.00109	CcSEcCtD
Danazol—Oedema—Mycophenolate mofetil—systemic scleroderma	6.99e-05	0.00109	CcSEcCtD
Danazol—AR—Generic Transcription Pathway—SMAD7—systemic scleroderma	6.96e-05	0.00382	CbGpPWpGaD
Danazol—Eosinophilia—Methotrexate—systemic scleroderma	6.89e-05	0.00107	CcSEcCtD
Danazol—Fatigue—Lisinopril—systemic scleroderma	6.88e-05	0.00107	CcSEcCtD
Danazol—Shock—Mycophenolate mofetil—systemic scleroderma	6.88e-05	0.00107	CcSEcCtD
Danazol—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.84e-05	0.00107	CcSEcCtD
Danazol—Pancreatitis—Methotrexate—systemic scleroderma	6.83e-05	0.00106	CcSEcCtD
Danazol—Constipation—Lisinopril—systemic scleroderma	6.82e-05	0.00106	CcSEcCtD
Danazol—Tachycardia—Mycophenolate mofetil—systemic scleroderma	6.82e-05	0.00106	CcSEcCtD
Danazol—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.76e-05	0.00105	CcSEcCtD
Danazol—Haemoglobin—Prednisone—systemic scleroderma	6.7e-05	0.00104	CcSEcCtD
Danazol—Nausea—Captopril—systemic scleroderma	6.69e-05	0.00104	CcSEcCtD
Danazol—Haemorrhage—Prednisone—systemic scleroderma	6.67e-05	0.00104	CcSEcCtD
Danazol—Asthenia—Leflunomide—systemic scleroderma	6.66e-05	0.00104	CcSEcCtD
Danazol—Pruritus—Leflunomide—systemic scleroderma	6.57e-05	0.00102	CcSEcCtD
Danazol—CCL2—Fluorometholone—Prednisone—systemic scleroderma	6.55e-05	0.03	CbGdCrCtD
Danazol—GNRHR—GPCR downstream signaling—RHOB—systemic scleroderma	6.54e-05	0.00359	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—CCL2—systemic scleroderma	6.5e-05	0.00357	CbGpPWpGaD
Danazol—Dizziness—Azathioprine—systemic scleroderma	6.5e-05	0.00101	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—RHOB—systemic scleroderma	6.49e-05	0.00356	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	6.47e-05	0.00355	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—EDN1—systemic scleroderma	6.46e-05	0.00355	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	6.37e-05	0.000992	CcSEcCtD
Danazol—Photosensitivity reaction—Methotrexate—systemic scleroderma	6.35e-05	0.00099	CcSEcCtD
Danazol—Asthenia—Mycophenolic acid—systemic scleroderma	6.35e-05	0.00099	CcSEcCtD
Danazol—Urticaria—Lisinopril—systemic scleroderma	6.34e-05	0.000988	CcSEcCtD
Danazol—Body temperature increased—Lisinopril—systemic scleroderma	6.31e-05	0.000983	CcSEcCtD
Danazol—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	6.28e-05	0.000978	CcSEcCtD
Danazol—Pruritus—Mycophenolic acid—systemic scleroderma	6.27e-05	0.000976	CcSEcCtD
Danazol—Vomiting—Azathioprine—systemic scleroderma	6.25e-05	0.000974	CcSEcCtD
Danazol—Rash—Azathioprine—systemic scleroderma	6.2e-05	0.000966	CcSEcCtD
Danazol—Dermatitis—Azathioprine—systemic scleroderma	6.19e-05	0.000965	CcSEcCtD
Danazol—Flushing—Prednisone—systemic scleroderma	6.19e-05	0.000964	CcSEcCtD
Danazol—Headache—Azathioprine—systemic scleroderma	6.16e-05	0.00096	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	6.15e-05	0.000959	CcSEcCtD
Danazol—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.15e-05	0.000959	CcSEcCtD
Danazol—Dizziness—Leflunomide—systemic scleroderma	6.14e-05	0.000957	CcSEcCtD
Danazol—Constipation—Mycophenolate mofetil—systemic scleroderma	5.98e-05	0.000931	CcSEcCtD
Danazol—Sweating—Methotrexate—systemic scleroderma	5.95e-05	0.000927	CcSEcCtD
Danazol—CCL2—Metabolism of proteins—ACE—systemic scleroderma	5.95e-05	0.00327	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—RHOB—systemic scleroderma	5.94e-05	0.00326	CbGpPWpGaD
Danazol—Haematuria—Methotrexate—systemic scleroderma	5.92e-05	0.000922	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—EDN1—systemic scleroderma	5.91e-05	0.00324	CbGpPWpGaD
Danazol—Vomiting—Leflunomide—systemic scleroderma	5.9e-05	0.00092	CcSEcCtD
Danazol—Alopecia—Prednisone—systemic scleroderma	5.89e-05	0.000918	CcSEcCtD
Danazol—Dizziness—Mycophenolic acid—systemic scleroderma	5.86e-05	0.000913	CcSEcCtD
Danazol—Rash—Leflunomide—systemic scleroderma	5.85e-05	0.000912	CcSEcCtD
Danazol—Dermatitis—Leflunomide—systemic scleroderma	5.85e-05	0.000911	CcSEcCtD
Danazol—Nausea—Azathioprine—systemic scleroderma	5.84e-05	0.00091	CcSEcCtD
Danazol—Headache—Leflunomide—systemic scleroderma	5.82e-05	0.000906	CcSEcCtD
Danazol—Asthenia—Lisinopril—systemic scleroderma	5.72e-05	0.000892	CcSEcCtD
Danazol—Pruritus—Lisinopril—systemic scleroderma	5.64e-05	0.000879	CcSEcCtD
Danazol—Vomiting—Mycophenolic acid—systemic scleroderma	5.63e-05	0.000878	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	5.61e-05	0.00308	CbGpPWpGaD
Danazol—Haemoglobin—Methotrexate—systemic scleroderma	5.6e-05	0.000873	CcSEcCtD
Danazol—Rash—Mycophenolic acid—systemic scleroderma	5.58e-05	0.00087	CcSEcCtD
Danazol—Dermatitis—Mycophenolic acid—systemic scleroderma	5.58e-05	0.000869	CcSEcCtD
Danazol—Haemorrhage—Methotrexate—systemic scleroderma	5.57e-05	0.000868	CcSEcCtD
Danazol—Urticaria—Mycophenolate mofetil—systemic scleroderma	5.55e-05	0.000865	CcSEcCtD
Danazol—Headache—Mycophenolic acid—systemic scleroderma	5.55e-05	0.000865	CcSEcCtD
Danazol—CCL2—Clobetasol propionate—Prednisone—systemic scleroderma	5.54e-05	0.0254	CbGdCrCtD
Danazol—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.52e-05	0.000861	CcSEcCtD
Danazol—Nausea—Leflunomide—systemic scleroderma	5.51e-05	0.000859	CcSEcCtD
Danazol—ESR1—Leptin signaling pathway—NOS3—systemic scleroderma	5.49e-05	0.00301	CbGpPWpGaD
Danazol—Vision blurred—Prednisone—systemic scleroderma	5.47e-05	0.000853	CcSEcCtD
Danazol—CCL2—Flunisolide—Prednisone—systemic scleroderma	5.46e-05	0.0251	CbGdCrCtD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	5.43e-05	0.00298	CbGpPWpGaD
Danazol—CCL2—Triamcinolone—Prednisone—systemic scleroderma	5.41e-05	0.0248	CbGdCrCtD
Danazol—Visual impairment—Methotrexate—systemic scleroderma	5.37e-05	0.000837	CcSEcCtD
Danazol—ESR1—Generic Transcription Pathway—SMAD7—systemic scleroderma	5.36e-05	0.00294	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	5.3e-05	0.00291	CbGpPWpGaD
Danazol—Dizziness—Lisinopril—systemic scleroderma	5.27e-05	0.000822	CcSEcCtD
Danazol—Erythema multiforme—Methotrexate—systemic scleroderma	5.27e-05	0.000821	CcSEcCtD
Danazol—Nausea—Mycophenolic acid—systemic scleroderma	5.26e-05	0.00082	CcSEcCtD
Danazol—Vertigo—Prednisone—systemic scleroderma	5.21e-05	0.000813	CcSEcCtD
Danazol—Syncope—Prednisone—systemic scleroderma	5.21e-05	0.000811	CcSEcCtD
Danazol—CCL2—Desoximetasone—Prednisone—systemic scleroderma	5.14e-05	0.0236	CbGdCrCtD
Danazol—Loss of consciousness—Prednisone—systemic scleroderma	5.1e-05	0.000795	CcSEcCtD
Danazol—Vomiting—Lisinopril—systemic scleroderma	5.07e-05	0.00079	CcSEcCtD
Danazol—PGR—Generic Transcription Pathway—CTGF—systemic scleroderma	5.05e-05	0.00277	CbGpPWpGaD
Danazol—Rash—Lisinopril—systemic scleroderma	5.03e-05	0.000784	CcSEcCtD
Danazol—Convulsion—Prednisone—systemic scleroderma	5.03e-05	0.000784	CcSEcCtD
Danazol—Dermatitis—Lisinopril—systemic scleroderma	5.02e-05	0.000783	CcSEcCtD
Danazol—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.01e-05	0.000781	CcSEcCtD
Danazol—Hypertension—Prednisone—systemic scleroderma	5.01e-05	0.000781	CcSEcCtD
Danazol—Chills—Methotrexate—systemic scleroderma	5e-05	0.000779	CcSEcCtD
Danazol—Headache—Lisinopril—systemic scleroderma	5e-05	0.000779	CcSEcCtD
Danazol—CCL2—Diflorasone—Prednisone—systemic scleroderma	4.99e-05	0.0229	CbGdCrCtD
Danazol—CCL2—Signaling Pathways—SMAD7—systemic scleroderma	4.96e-05	0.00272	CbGpPWpGaD
Danazol—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.94e-05	0.000771	CcSEcCtD
Danazol—Arthralgia—Prednisone—systemic scleroderma	4.94e-05	0.00077	CcSEcCtD
Danazol—Anxiety—Prednisone—systemic scleroderma	4.92e-05	0.000767	CcSEcCtD
Danazol—Alopecia—Methotrexate—systemic scleroderma	4.92e-05	0.000767	CcSEcCtD
Danazol—CCL2—Betamethasone—Mometasone—systemic scleroderma	4.9e-05	0.0225	CbGdCrCtD
Danazol—CCL2—Dexamethasone—Mometasone—systemic scleroderma	4.9e-05	0.0225	CbGdCrCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	4.83e-05	0.00265	CbGpPWpGaD
Danazol—Nausea—Lisinopril—systemic scleroderma	4.74e-05	0.000738	CcSEcCtD
Danazol—Oedema—Prednisone—systemic scleroderma	4.74e-05	0.000738	CcSEcCtD
Danazol—Back pain—Methotrexate—systemic scleroderma	4.69e-05	0.000731	CcSEcCtD
Danazol—ESR1—Leptin signaling pathway—IL1B—systemic scleroderma	4.67e-05	0.00256	CbGpPWpGaD
Danazol—Shock—Prednisone—systemic scleroderma	4.66e-05	0.000726	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—MMP9—systemic scleroderma	4.65e-05	0.00255	CbGpPWpGaD
Danazol—Tachycardia—Prednisone—systemic scleroderma	4.62e-05	0.000721	CcSEcCtD
Danazol—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.62e-05	0.00072	CcSEcCtD
Danazol—Hyperhidrosis—Prednisone—systemic scleroderma	4.58e-05	0.000714	CcSEcCtD
Danazol—Vision blurred—Methotrexate—systemic scleroderma	4.57e-05	0.000713	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—SMAD7—systemic scleroderma	4.53e-05	0.00249	CbGpPWpGaD
Danazol—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.44e-05	0.000693	CcSEcCtD
Danazol—Rash—Mycophenolate mofetil—systemic scleroderma	4.41e-05	0.000687	CcSEcCtD
Danazol—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.4e-05	0.000686	CcSEcCtD
Danazol—PGR—Gene Expression—SMAD7—systemic scleroderma	4.4e-05	0.00241	CbGpPWpGaD
Danazol—Headache—Mycophenolate mofetil—systemic scleroderma	4.38e-05	0.000682	CcSEcCtD
Danazol—CCL2—Budesonide—Prednisone—systemic scleroderma	4.37e-05	0.02	CbGdCrCtD
Danazol—Vertigo—Methotrexate—systemic scleroderma	4.36e-05	0.000679	CcSEcCtD
Danazol—Leukopenia—Methotrexate—systemic scleroderma	4.34e-05	0.000677	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	4.32e-05	0.00237	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.32e-05	0.000673	CcSEcCtD
Danazol—Paraesthesia—Prednisone—systemic scleroderma	4.25e-05	0.000663	CcSEcCtD
Danazol—Convulsion—Methotrexate—systemic scleroderma	4.2e-05	0.000655	CcSEcCtD
Danazol—Dyspepsia—Prednisone—systemic scleroderma	4.17e-05	0.00065	CcSEcCtD
Danazol—Nausea—Mycophenolate mofetil—systemic scleroderma	4.15e-05	0.000647	CcSEcCtD
Danazol—Arthralgia—Methotrexate—systemic scleroderma	4.13e-05	0.000644	CcSEcCtD
Danazol—PGR—Gene Expression—TNFSF13—systemic scleroderma	4.09e-05	0.00224	CbGpPWpGaD
Danazol—Fatigue—Prednisone—systemic scleroderma	4.08e-05	0.000637	CcSEcCtD
Danazol—Constipation—Prednisone—systemic scleroderma	4.05e-05	0.000631	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—CCL2—systemic scleroderma	4.04e-05	0.00222	CbGpPWpGaD
Danazol—ESR1—Regulation of Telomerase—TGFB1—systemic scleroderma	3.92e-05	0.00215	CbGpPWpGaD
Danazol—Thrombocytopenia—Methotrexate—systemic scleroderma	3.88e-05	0.000604	CcSEcCtD
Danazol—AR—Generic Transcription Pathway—CTGF—systemic scleroderma	3.85e-05	0.00211	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RHOB—systemic scleroderma	3.84e-05	0.00211	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—TGFB1—systemic scleroderma	3.83e-05	0.0021	CbGpPWpGaD
Danazol—Hyperhidrosis—Methotrexate—systemic scleroderma	3.83e-05	0.000596	CcSEcCtD
Danazol—CCL2—Metabolism of proteins—MMP1—systemic scleroderma	3.82e-05	0.0021	CbGpPWpGaD
Danazol—Urticaria—Prednisone—systemic scleroderma	3.76e-05	0.000587	CcSEcCtD
Danazol—Body temperature increased—Prednisone—systemic scleroderma	3.74e-05	0.000584	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.67e-05	0.00202	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HSPG2—systemic scleroderma	3.62e-05	0.00199	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.61e-05	0.000562	CcSEcCtD
Danazol—Paraesthesia—Methotrexate—systemic scleroderma	3.56e-05	0.000554	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—RHOB—systemic scleroderma	3.51e-05	0.00193	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CSK—systemic scleroderma	3.49e-05	0.00192	CbGpPWpGaD
Danazol—Dyspepsia—Methotrexate—systemic scleroderma	3.48e-05	0.000543	CcSEcCtD
Danazol—Fatigue—Methotrexate—systemic scleroderma	3.41e-05	0.000532	CcSEcCtD
Danazol—Asthenia—Prednisone—systemic scleroderma	3.4e-05	0.00053	CcSEcCtD
Danazol—AR—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	3.37e-05	0.00185	CbGpPWpGaD
Danazol—Pruritus—Prednisone—systemic scleroderma	3.35e-05	0.000522	CcSEcCtD
Danazol—AR—Gene Expression—SMAD7—systemic scleroderma	3.35e-05	0.00184	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—EDN1—systemic scleroderma	3.34e-05	0.00183	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—EDN1—systemic scleroderma	3.31e-05	0.00182	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HSPG2—systemic scleroderma	3.31e-05	0.00182	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CSK—systemic scleroderma	3.19e-05	0.00175	CbGpPWpGaD
Danazol—Urticaria—Methotrexate—systemic scleroderma	3.15e-05	0.00049	CcSEcCtD
Danazol—Dizziness—Prednisone—systemic scleroderma	3.13e-05	0.000488	CcSEcCtD
Danazol—Body temperature increased—Methotrexate—systemic scleroderma	3.13e-05	0.000488	CcSEcCtD
Danazol—AR—Gene Expression—TNFSF13—systemic scleroderma	3.11e-05	0.00171	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—EDN1—systemic scleroderma	3.03e-05	0.00166	CbGpPWpGaD
Danazol—Vomiting—Prednisone—systemic scleroderma	3.01e-05	0.000469	CcSEcCtD
Danazol—Rash—Prednisone—systemic scleroderma	2.99e-05	0.000466	CcSEcCtD
Danazol—Dermatitis—Prednisone—systemic scleroderma	2.98e-05	0.000465	CcSEcCtD
Danazol—Headache—Prednisone—systemic scleroderma	2.97e-05	0.000463	CcSEcCtD
Danazol—ESR1—Generic Transcription Pathway—CTGF—systemic scleroderma	2.96e-05	0.00163	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—MMP2—systemic scleroderma	2.96e-05	0.00162	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SMAD7—systemic scleroderma	2.86e-05	0.00157	CbGpPWpGaD
Danazol—Asthenia—Methotrexate—systemic scleroderma	2.84e-05	0.000443	CcSEcCtD
Danazol—Nausea—Prednisone—systemic scleroderma	2.81e-05	0.000439	CcSEcCtD
Danazol—Pruritus—Methotrexate—systemic scleroderma	2.8e-05	0.000437	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.78e-05	0.00153	CbGpPWpGaD
Danazol—CCL2—Betamethasone—Prednisone—systemic scleroderma	2.67e-05	0.0123	CbGdCrCtD
Danazol—CCL2—Dexamethasone—Prednisone—systemic scleroderma	2.67e-05	0.0123	CbGdCrCtD
Danazol—Dizziness—Methotrexate—systemic scleroderma	2.62e-05	0.000408	CcSEcCtD
Danazol—ESR1—Gene Expression—SMAD7—systemic scleroderma	2.58e-05	0.00142	CbGpPWpGaD
Danazol—Vomiting—Methotrexate—systemic scleroderma	2.52e-05	0.000392	CcSEcCtD
Danazol—Rash—Methotrexate—systemic scleroderma	2.5e-05	0.000389	CcSEcCtD
Danazol—Dermatitis—Methotrexate—systemic scleroderma	2.49e-05	0.000389	CcSEcCtD
Danazol—Headache—Methotrexate—systemic scleroderma	2.48e-05	0.000387	CcSEcCtD
Danazol—PGR—Gene Expression—CTGF—systemic scleroderma	2.43e-05	0.00133	CbGpPWpGaD
Danazol—ESR1—Gene Expression—TNFSF13—systemic scleroderma	2.4e-05	0.00132	CbGpPWpGaD
Danazol—Nausea—Methotrexate—systemic scleroderma	2.35e-05	0.000366	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.23e-05	0.00122	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RHOB—systemic scleroderma	2.21e-05	0.00121	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HSPG2—systemic scleroderma	2.09e-05	0.00115	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CCL2—systemic scleroderma	2.07e-05	0.00114	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CSK—systemic scleroderma	2.01e-05	0.00111	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—EDN1—systemic scleroderma	1.96e-05	0.00107	CbGpPWpGaD
Danazol—AR—Gene Expression—CTGF—systemic scleroderma	1.85e-05	0.00102	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—EDN1—systemic scleroderma	1.79e-05	0.000983	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.72e-05	0.000943	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SMAD7—systemic scleroderma	1.68e-05	0.000921	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—HSPG2—systemic scleroderma	1.64e-05	0.000898	CbGpPWpGaD
Danazol—ESR1—Gene Expression—CTGF—systemic scleroderma	1.43e-05	0.000783	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RHOB—systemic scleroderma	1.3e-05	0.000713	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CTGF—systemic scleroderma	1.24e-05	0.00068	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HSPG2—systemic scleroderma	1.22e-05	0.000672	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCL2—systemic scleroderma	1.22e-05	0.000672	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NOS3—systemic scleroderma	1.19e-05	0.000655	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CSK—systemic scleroderma	1.18e-05	0.000649	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EDN1—systemic scleroderma	1.13e-05	0.00062	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NOS3—systemic scleroderma	1.09e-05	0.000599	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MMP9—systemic scleroderma	9.57e-06	0.000525	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MMP9—systemic scleroderma	8.75e-06	0.000481	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TGFB1—systemic scleroderma	7.89e-06	0.000433	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCL2—systemic scleroderma	7.72e-06	0.000424	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TGFB1—systemic scleroderma	7.22e-06	0.000396	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NOS3—systemic scleroderma	6.88e-06	0.000378	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EDN1—systemic scleroderma	6.63e-06	0.000364	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MMP9—systemic scleroderma	5.52e-06	0.000303	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—NOS3—systemic scleroderma	5.39e-06	0.000296	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—HSPG2—systemic scleroderma	4.77e-06	0.000262	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TGFB1—systemic scleroderma	4.55e-06	0.00025	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCL2—systemic scleroderma	4.53e-06	0.000249	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NOS3—systemic scleroderma	4.04e-06	0.000222	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CTGF—systemic scleroderma	3.62e-06	0.000199	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MMP9—systemic scleroderma	3.24e-06	0.000178	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TGFB1—systemic scleroderma	2.67e-06	0.000147	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.57e-06	8.64e-05	CbGpPWpGaD
